1. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
- Author
-
Luca Valenti, Serena Pelusi, Alessio Aghemo, Sara Gritti, Luisa Pasulo, Cristiana Bianco, Claudia Iegri, Giuliana Cologni, Elisabetta Degasperi, Roberta D’Ambrosio, Paolo delPoggio, Alessandro Soria, Massimo Puoti, Isabella Carderi, Marie Graciella Pigozzi, Canio Carriero, Angiola Spinetti, Valentina Zuccaro, Massimo Memoli, Alessia Giorgini, Mauro Viganò, Maria Grazia Rumi, Tiziana Re, Ombretta Spinelli, Maria Chiara Colombo, Tiziana Quirino, Barbara Menzaghi, Gianpaolo Lorini, Angelo Pan, Antonella D’Arminio Monforte, Elisabetta Buscarini, Aldo Autolitano, Paolo Bonfanti, Natalia Terreni, Gianpiero Aimo, Monia Mendeni, Daniele Prati, Pietro Lampertico, Massimo Colombo, Stefano Fagiuoli, and for the NAVIGATORE‐Lombardia Network
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real‐life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE‐Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow‐up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m2, 1.03‐1.09) and diabetes (OR 2.01 [1.65‐2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35‐0.60]; P
- Published
- 2022
- Full Text
- View/download PDF